Vascular Improvement With Olmesartan Medoxomil Study

Completed · Phase 4

Conditions studied: Hypertension

In brief

The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.

Key facts

Study ID

NCT00772499

Run by

Daiichi Sankyo

People needed

100

Starts

2002-11-01

Expected to finish

2005-07-01

Last updated by the study team

2008-10-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female
• 18-75 years of age
• Mean seated diastolic BP 90-109 or mean seated systolic BP of 140-179

You may not qualify if…

• Secondary hypertension
• Renal disease
• Diabetes mellitus
• Serum creatinine >3.0 mg/dL
• Hemoglobin <10 mg/dL (males) or <9mg/dL (females)
• WBC count <2000 cells/mL
• Platelet count <100,000 cells/mL
• Either ALT \& AST >2.5 x upper limit of normal
• BMI >35 kg/m2
• TIA or cerebrovascular attack within 3 months of study entry

Where it is running

• Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.